Identification of COVID-19 Infection in Vulnerable Population and Its Prevention and Treatment Perspectives

doi:10.12114/j.issn.1007-9572.2023.0230

Chinese General Practice ›› 2024, Vol. 27 ›› Issue (02): 132-137.DOI: 10.12114/j.issn.1007-9572.2023.0230

Special Issue: 新型冠状病毒肺炎最新文章合辑； COVID-19疫情防控研究；述评栏目最新文章合辑；医防融合最新文章合辑

• Commentary • Previous Articles Next Articles

Identification of COVID-19 Infection in Vulnerable Population and Its Prevention and Treatment Perspectives

¹The First Affiliated Hospital of Guangzhou Medical University/National Clinical Research Center for Respiratory Diseases/State Key Laboratory of Respiratory Diseases/National Center for Respiratory Medicine/Guangzhou Institute of Respiratory Health, Guangzhou 510120, China
²Department of Kidney Transplantation, Kidney Disease Hospital, the First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an 710061, China
³Harbin Institute of Hematology and Tumor, Harbin 150010, China
⁴Department of Rheumatology and Immunology, Peking Union Medical College, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital/National Clinical Research Center for Dermatological and Immunological Diseases/State Key Laboratory of Severe and Rare Diseases/Key Laboratory of Rheumatology and Immunology, Ministry of Education, Beijing 100730, China

Received:2023-04-11 Revised:2023-05-29 Published:2024-01-15 Online:2023-10-23
Contact: ZHENG Jinping

新型冠状病毒感染脆弱人群的识别及防治展望

¹510120　广东省广州市，广州医科大学附属第一医院　国家呼吸系统疾病临床医学研究中心　国家呼吸医学中心　呼吸疾病全国重点实验室　广州呼吸健康研究院
²710061　陕西省西安市，西安交通大学第一附属医院肾脏病医院肾移植科
³150010　黑龙江省哈尔滨市，哈尔滨血液病肿瘤研究所
⁴100730　北京市，中国医学科学院北京协和医学院　北京协和医院风湿免疫科　国家皮肤与免疫疾病临床医学研究中心　疑难重症及罕见病国家重点实验室　风湿免疫病学教育部重点实验室

通讯作者: 郑劲平
作者简介:
作者贡献：郑劲平负责文章构思与设计、文献检索筛选及论文撰写修改；薛武军、巨春蓉、马军、曾小峰负责结果解读分析及文章修改审校。所有作者确认了文章终稿，对文章整体负责、监督管理。

Abstract

Abstract:

The COVID-19 pandemic has devastated human health and global economy. Diminished immune function of health-related vulnerable populations leads to insufficient protective effect of the vaccine with a higher risk of severe illness and death following infection, and there is a lack of adequate targeted drugs for the prevention and treatment of COVID-19. In the context that COVID-19 treated as a Category B disease in China, vulnerable populations have become the priority populations for epidemic prevention and control. Therefore, the strategies of individual immunization and prevention should be further optimized for vulnerable populations. In addition to vaccines, other prevention strategies should be supplemented, such as long-acting neutralizing antibodies. Based on this, this paper reviews the identification, immune function characteristics and prevention strategies of COVID-19 in vulnerable populations, to provide a reference for the prevention and control strategies for health-related vulnerable populations in China, expecting that more suitable preventive drugs for vulnerable populations can be developed in the future to reduce the risk of COVID-19 in vulnerable populations.

Key words: COVID-19, Vulnerable populations, Long-acting neutralizing antibody, Prevention, Review

摘要：

新型冠状病毒感染疫情对人类健康和全球经济造成重创。健康相关脆弱人群的免疫功能减退，导致疫苗的防护效果不足，并且，感染新型冠状病毒后重症和死亡风险更高，而目前尚缺乏足够有针对性的新型冠状病毒感染预防和治疗药物。在我国"乙类乙管"的防疫背景下，脆弱人群成为疫情防控的重点人群。因此，针对脆弱人群应该进一步优化个体免疫和防控策略，在疫苗之外，还需要补充其他预防手段，如长效中和抗体。基于此，本文将对脆弱人群的识别、免疫功能特点与预防方法进行综述，为国内健康相关脆弱人群的防治策略提供参考，期待未来可以研发出更适宜脆弱人群的预防药物，降低脆弱人群感染新型冠状病毒的风险。

关键词: 新型冠状病毒感染, 脆弱人群, 长效中和抗体, 预防, 综述

ZHENG Jinping,XUE Wujun,JU Chunrong, et al. Identification of COVID-19 Infection in Vulnerable Population and Its Prevention and Treatment Perspectives[J]. Chinese General Practice, 2024, 27(02): 132-137. DOI: 10.12114/j.issn.1007-9572.2023.0230.
郑劲平,薛武军,巨春蓉等. 新型冠状病毒感染脆弱人群的识别及防治展望[J]. 中国全科医学, 2024, 27(02): 132-137. DOI: 10.12114/j.issn.1007-9572.2023.0230.

Figures/Tables 1

References 67

[1]	WHO Coronavirus （COVID-19） Dashboard[EB/OL].[2023-02-15].
[2]	PLUMB I D，FELDSTEIN L R，BARKLEY E，et al. Effectiveness of COVID-19 mRNA vaccination in preventing COVID-19-associated hospitalization among adults with previous SARS-CoV-2 infection - United States，June 2021-february 2022[J]. MMWR Morb Mortal Wkly Rep，2022，71（15）：549-555. DOI：10.15585/mmwr.mm7115e2.
[3]	WAISEL D B. Vulnerable populations in healthcare[J]. Curr Opin Anaesthesiol，2013，26（2）：186-192. DOI：10.1097/ACO.0b013e32835e8c17.
[4]	LEE A R Y B，WONG S Y，CHAI L Y A，et al. Efficacy of covid-19 vaccines in immunocompromised patients：systematic review and meta-analysis[J]. BMJ，2022，376：e068632. DOI：10.1136/bmj-2021-068632.
[5]	SHEN C，RISK M，SCHIOPU E，et al. Efficacy of COVID-19 vaccines in patients taking immunosuppressants[J]. Ann Rheum Dis，2022，81（6）：875-880. DOI：10.1136/annrheumdis-2021-222045.
[6]	PARKER E P K，DESAI S，MARTI M，et al. Response to additional COVID-19 vaccine doses in people who are immunocompromised：a rapid review[J]. Lancet Glob Health，2022，10（3）：e326-328. DOI：10.1016/S2214-109X(21)00593-3.
[7]	JANUEL E，DE SEZE J，VERMERSCH P，et al. Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica[J]. Mult Scler，2022，28（7）：1155-1159. DOI：10.1177/13524585211049737.
[8]	GEORGE J A，MAPHAYI M R，PILLAY T. COVID-19 and vulnerable populations in sub-saharan Africa[J]. Adv Exp Med Biol，2021，1321：147-162. DOI：10.1007/978-3-030-59261-5_13.
[9]	OUYANG H，MA X H，WU X. The prevalence and determinants of COVID-19 vaccine hesitancy in the age of infodemic[J]. Hum Vaccin Immunother，2022，18（1）：2013694. DOI：10.1080/21645515.2021.2013694.
[10]	XU J B，ZHAO S Z，TENG T S，et al. Systematic comparison of two animal-to-human transmitted human coronaviruses：SARS-CoV-2 and SARS-CoV[J]. Viruses，2020，12（2）：244. DOI：10.3390/v12020244.
[11]	YUAN M，WU N C，ZHU X Y，et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV[J]. Science，2020，368（6491）：630-633. DOI：10.1126/science.abb7269.
[12]	WANG Q H，ZHANG Y F，WU L L，et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2[J]. Cell，2020，181（4）：894-904.e9. DOI：10.1016/j.cell.2020.03.045.
[13]	WALLS A C，PARK Y J，TORTORICI M A，et al. Structure，function，and antigenicity of the SARS-CoV-2 spike glycoprotein[J]. Cell，2020，181（2）：281-292.e6. DOI：10.1016/j.cell.2020.02.058.
[14]	MEYER C U，ZEPP F. Principles in immunology for the design and development of vaccines[J]. Methods Mol Biol，2022，2410：27-56. DOI：10.1007/978-1-0716-1884-4_2.
[15]	PANDA A，ARJONA A，SAPEY E，et al. Human innate immunosenescence：causes and consequences for immunity in old age[J]. Trends Immunol，2009，30（7）：325-333. DOI：10.1016/j.it.2009.05.004.
[16]	ABIRI B，AHMADI A R，HEJAZI M，et al. Obesity，diabetes mellitus，and metabolic syndrome：review in the era of COVID-19[J]. Clin Nutr Res，2022，11（4）：331-346. DOI：10.7762/cnr.2022.11.4.331.
[17]	LIM S，BAE J H，KWON H S，et al. COVID-19 and diabetes mellitus：from pathophysiology to clinical management[J]. Nat Rev Endocrinol，2021，17（1）：11-30. DOI：10.1038/s41574-020-00435-4.
[18]	MOHAMMAD S，AZIZ R，AL MAHRI S，et al. Obesity and COVID-19：what makes obese host so vulnerable?[J]. Immun Ageing，2021，18（1）：1. DOI：10.1186/s12979-020-00212-x.
[19]	MARDOMI A，KHOSROSHAHI H T. Dialysis-induced immune dysregulations and their possible impacts on COVID-19[J]. Iran J Kidney Dis，2021，15（3）：161-167.
[20]	FAHRNER J E，LAHMAR I，GOUBET A G，et al. The polarity and specificity of antiviral T lymphocyte responses determine susceptibility to SARS-CoV-2 infection in patients with cancer and healthy individuals[J]. Cancer Discov，2022，12（4）：958-983. DOI：10.1158/2159-8290.CD-21-1441.
[21]	FERNANDEZ SALINAS A，PIANO MORTARI E，TERRERI S，et al. Impaired memory B-cell response to the Pfizer-BioNTech COVID-19 vaccine in patients with common variable immunodeficiency[J]. J Allergy Clin Immunol，2022，149（1）：76-77. DOI：10.1016/j.jaci.2021.08.031.
[22]	CAJAMARCA-BARON J，GUAVITA-NAVARRO D，BUITRAGO-BOHORQUEZ J，et al. SARS-CoV-2 （COVID-19） in patients with some degree of immunosuppression[J]. Reumatol Clin，2021，17（7）：408-419. DOI：10.1016/j.reumae.2020.08.001.
[23]	SICA A，COLOMBO M P，TRAMA A，et al. Immunometabolic status of COVID-19 cancer patients[J]. Physiol Rev，2020，100（4）：1839-1850. DOI：10.1152/physrev.00018.2020.
[24]	MOR G，ALDO P，ALVERO A B. The unique immunological and microbial aspects of pregnancy[J]. Nat Rev Immunol，2017，17（8）：469-482. DOI：10.1038/nri.2017.64.
[25]	SCHUMACHER A，COSTA S D，ZENCLUSSEN A C. Endocrine factors modulating immune responses in pregnancy[J]. Front Immunol，2014，5：196. DOI：10.3389/fimmu.2014.00196.
[26]	WOLTER N，JASSAT W，WALAZA S，et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa：a data linkage study[J]. Lancet，2022，399（10323）：437-446. DOI：10.1016/S0140-6736(22)00017-4.
[27]	(新华全媒+)最新发布：2022年12月8日至2023年1月12日全国在院新冠病毒感染相关死亡病例近6万例平均年龄80.3岁[EB/OL].（2023-01-14）[2023-03-22].
[28]	DE GIORGI A，FABBIAN F，GRECO S，et al. Prediction of in-hospital mortality of patients with SARS-CoV-2 infection by comorbidity indexes：an Italian internal medicine single center study[J]. Eur Rev Med Pharmacol Sci，2020，24（19）：10258-10266. DOI：10.26355/eurrev_202010_23250.
[29]	DOMINGUEZ-RAMIREZ L，RODRIGUEZ-PEREZ F，SOSA-JURADO F，et al. The role of metabolic comorbidity in COVID-19 mortality of middle-aged adults. The case of Mexico[J]. medRxiv，2020. DOI：10.1101/2020.12.15.20244160.
[30]	ROSENTHAL N，CAO Z，GUNDRUM J，et al. Risk factors associated with In-hospital mortality in a US national sample of patients with COVID-19[J]. JAMA Netw Open，2020，3（12）：e2029058. DOI：10.1001/jamanetworkopen.2020.29058.
[31]	HARPAZ R，DAHL R M，DOOLING K L. Prevalence of immunosuppression among US adults，2013[J]. JAMA，2016，316（23）：2547-2548. DOI：10.1001/jama.2016.16477.
[32]	OWEN C，ROBINSON S，CHRISTOFIDES A，et al. A Canadian perspective：monoclonal antibodies for pre- and post-exposure protection from COVID-19 in vulnerable patients with hematological malignancies[J]. Curr Oncol，2022，29（6）：3940-3949. DOI：10.3390/curroncol29060315.
[33]	JAMIESON D J，RASMUSSEN S A. An update on COVID-19 and pregnancy[J]. Am J Obstet Gynecol，2022，226（2）：177-186. DOI：10.1016/j.ajog.2021.08.054.
[34]	ZAMBRANO L D，ELLINGTON S，STRID P，et al. Update：characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States，January 22-october 3，2020[J]. MMWR Morb Mortal Wkly Rep，2020，69（44）：1641-1647. DOI：10.15585/mmwr.mm6944e3.
[35]	ATTAWAY A H，SCHERAGA R G，BHIMRAJ A，et al. Severe covid-19 pneumonia：pathogenesis and clinical management[J]. BMJ，2021，372：n436. DOI：10.1136/bmj.n436.
[36]	RAMAN B，BLUEMKE D A，LÜSCHER T F，et al. Long COVID：post-acute sequelae of COVID-19 with a cardiovascular focus[J]. Eur Heart J，2022，43（11）：1157-1172. DOI：10.1093/eurheartj/ehac031.
[37]	PIJLS B G，JOLANI S，ATHERLEY A，et al. Demographic risk factors for COVID-19 infection，severity，ICU admission and death：a meta-analysis of 59 studies[J]. BMJ Open，2021，11（1）：e044640. DOI：10.1136/bmjopen-2020-044640.
[38]	GUR R E，WHITE L K，WALLER R，et al. The disproportionate burden of the COVID-19 pandemic among pregnant black women[J]. Psychiatry Res，2020，293：113475. DOI：10.1016/j.psychres.2020.113475.
[39]	KHERA R，JAIN S，LIN Z Q，et al. Evaluation of the anticipated burden of COVID-19 on hospital-based healthcare services across the United States[J]. medRxiv，2020. DOI：10.1101/2020.04.01.20050492.
[40]	AVANZATO V A，MATSON M J，SEIFERT S N，et al. Case study：prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer[J]. Cell，2020，183（7）：1901-1912.e9. DOI：10.1016/j.cell.2020.10.049.
[41]	COREY L，BEYRER C，COHEN M S，et al. SARS-CoV-2 variants in patients with immunosuppression[J]. N Engl J Med，2021，385（6）：562-566. DOI：10.1056/NEJMsb2104756.
[42]	CAI J，DENG X W，YANG J，et al. Modeling transmission of SARS-CoV-2 Omicron in China[J]. Nat Med，2022，28（7）：1468-1475. DOI：10.1038/s41591-022-01855-7.
[43]	LOPEZ BERNAL J，ANDREWS N，GOWER C，et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms，hospital admissions，and mortality in older adults in England：test negative case-control study[J]. BMJ，2021，373：n1088. DOI：10.1136/bmj.n1088.
[44]	YAN Z P，YANG M，LAI C L. COVID-19 vaccines：a review of the safety and efficacy of current clinical trials[J]. Pharmaceuticals，2021，14（5）：406. DOI：10.3390/ph14050406.
[45]	ZHU F C，ZHUANG C L，CHU K，et al. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults：randomised，double-blind，placebo-controlled，phase 1 and 2 trials[J]. Lancet Respir Med，2022，10（8）：749-760. DOI：10.1016/S2213-2600(22)00131-X.
[46]	FU Z Y，LIANG D G，ZHANG W，et al. Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai[J]. Front Med，2023. DOI：10.1007/s11684-022-0977-3.
[47]	KRICORIAN K，CIVEN R，EQUILS O. COVID-19 vaccine hesitancy：misinformation and perceptions of vaccine safety[J]. Hum Vaccin Immunother，2022，18（1）：1950504. DOI：10.1080/21645515.2021.1950504.
[48]	MURPHY J，VALLIÈRES F，BENTALL R P，et al. Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom[J]. Nat Commun，2021，12（1）：29. DOI：10.1038/s41467-020-20226-9.
[49]	TSAI R，HERVEY J，HOFFMAN K D，et al. COVID-19 vaccine hesitancy among individuals with cancer，autoimmune diseases，and other serious comorbid conditions[J]. JMIR Public Health Surveill，2022，8（1）：e29872. DOI：10.2196/29872.
[50]	PANTALEO G，CORREIA B，FENWICK C，et al. Antibodies to combat viral infections：development strategies and progress[J]. Nat Rev Drug Discov，2022，21（9）：676-696. DOI：10.1038/s41573-022-00495-3.
[51]	JAWORSKI J P. Neutralizing monoclonal antibodies for COVID-19 treatment and prevention[J]. Biomed J，2021，44（1）：7-17. DOI：10.1016/j.bj.2020.11.011.
[52]	新型冠状病毒感染诊疗方案（试行第十版）[EB/OL].[2023-03-11].
[53]	ZALEVSKY J，CHAMBERLAIN A K，HORTON H M，et al. Enhanced antibody half-life improves in vivo activity[J]. Nat Biotechnol，2010，28（2）：157-159. DOI：10.1038/nbt.1601.
[54]	Fact sheet for healthcare providers：emergency use authorization for bebtelovimab [EB/OL].[2022-11-01].
[55]	Fact sheet for health care providers emergency use authorization （EUA） of bamlanivimab and etesevimab [EB/OL].[2022-01-01].
[56]	Fact sheet for health care providers emergency use authorization（EUA） of REGEN-COV^® （casirivimab and imdevimab）[EB/OL].[2022-01-11].
[57]	Sotrovimab for COVID-19[J]. Aust Prescr，2021，44（5）：175. DOI：10.18773/austprescr.2021.051.
[58]	LEVIN M J，USTIANOMSKI A，DE WIT S，et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of COVID-19[J]. N Engl J Med，2022，386（23）：2188-2200. DOI：10.1056/NEJMoa2116620.
[59]	LEVIN M J，USTIANOWSKI A，DE WIT S，et al. Intramuscular AZD7442 （tixagevimab-cilgavimab） for prevention of covid-19[J]. N Engl J Med，2022，386（23）：2188-2200. DOI：10.1056/NEJMoa2116620.
[60]	STUVER R，SHAH G L，KORDE N S，et al. Activity of AZD7442 （tixagevimab-cilgavimab） against Omicron SARS-CoV-2 in patients with hematologic malignancies[J]. Cancer Cell，2022，40（6）：590-591. DOI：10.1016/j.ccell.2022.05.007.
[61]	AL JURDI A，MORENA L，COTE M，et al. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave[J]. Am J Transplant，2022，22（12）：3130-3136. DOI：10.1111/ajt.17128.
[62]	NGUYEN Y，FLAHAULT A，CHAVAROT N，et al. Pre-exposure prophylaxis with tixagevimab and cilgavimab （Evusheld） for COVID-19 among 1112 severely immunocompromised patients[J]. Clin Microbiol Infect，2022，28（12）：1654.e1-1651654.e4. DOI：10.1016/j.cmi.2022.07.015.
[63]	GRAU-PUJOL B，CAMPRUBÍ-FERRER D，MARTI-SOLER H，et al. Pre-exposure prophylaxis with hydroxychloroquine for COVID-19：a double-blind，placebo-controlled randomized clinical trial[J]. Trials，2021，22（1）：808. DOI：10.1186/s13063-021-05758-9.
[64]	MORGENSTERN J，REDONDO J N，OLAVARRIA A，et al. Ivermectin as a SARS-CoV-2 pre-exposure prophylaxis method in healthcare workers：a propensity score-matched retrospective cohort study[J]. Cureus，2021，13（8）：e17455. DOI：10.7759/cureus.17455.
[65]	OUYANG J，ZAONGO S D，HARYPURSAT V，et al. SARS-CoV-2 pre-exposure prophylaxis：a potential COVID-19 preventive strategy for high-risk populations，including healthcare workers，immunodeficient individuals，and poor vaccine responders[J]. Front Public Health，2022，10：945448. DOI：10.3389/fpubh.2022.945448.
[66]	GAJEWSKI A，KOŚMIDER A，NOWACKA A，et al. Potential of herbal products in prevention and treatment of COVID-19. Literature review[J]. Biomed Pharmacother，2021，143：112150. DOI：10.1016/j.biopha.2021.112150.
[67]	MA Q H，LI R F，PAN W Q，et al. Phillyrin （KD-1） exerts anti-viral and anti-inflammatory activities against novel coronavirus （SARS-CoV-2） and human coronavirus 229E （HCoV-229E） by suppressing the nuclear factor kappa B （NF-κB） signaling pathway[J]. Phytomedicine，2020，78：153296. DOI：10.1016/j.phymed.2020.153296.

评估标准	评估内容	评分（分）
年龄	<65岁	0
	65~80岁	1
	>80岁	2
基础疾病	无基础疾病	0
	基础疾病稳定	1
	基础疾病不稳定或基础疾病严重	2
疫苗接种	全程接种疫苗	0
	未全程接种疫苗	1
	未接种疫苗	2

评估标准	评估内容	评分（分）
年龄	<65岁	0
	65~80岁	1
	>80岁	2
基础疾病	无基础疾病	0
	基础疾病稳定	1
	基础疾病不稳定或基础疾病严重	2
疫苗接种	全程接种疫苗	0
	未全程接种疫苗	1
	未接种疫苗	2

Identification of COVID-19 Infection in Vulnerable Population and Its Prevention and Treatment Perspectives

新型冠状病毒感染脆弱人群的识别及防治展望

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 67

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	TIAN Chen, LIU Jianing, TIAN Jinhui, GE Long. Living Systematic Reviews: Methods and Processes for Development [J]. Chinese General Practice, 2025, 28(30): 3853-3860.
[2]	WANG Tingting, TANG Yong, ZHANG Wenke, LI Zhigang. Research Progress on Exercise Intervention of Hyperuricemia [J]. Chinese General Practice, 2025, 28(30): 3841-3846.
[3]	ZHOU Sheng, DENG Changsheng, ZOU Guanyang, SONG Jianping. Research Progress on the Pathogenesis of Complications of Malaria in Cardiovascular Diseases [J]. Chinese General Practice, 2025, 28(27): 3466-3472.
[4]	HUANG Yulin, WANG Haoyun, LI Yanmei, XIAO Xueying. Symptom Clusters in Gastric Cancer Patients Receiving Chemotherapy: a Scoping Review [J]. Chinese General Practice, 2025, 28(26): 3338-3344.
[5]	TANG Shangfeng, HUANG Yangzhen, ZHENG Yanxi, PAN Yangyang, XIONG Zhongbao, QING Hua, SONG Jia, WEI Yilin, DONG Heng, WANG Chunying, CHEN Manwei, ZHANG Kangkang. Specification for the Integration of Healthcare and Prevention Services in Diabetes at the Primary Level [J]. Chinese General Practice, 2025, 28(25): 3096-3103.
[6]	TANG Shangfeng, HUANG Yangzhen, PAN Yangyang, ZHENG Yanxi, XIONG Zhongbao, ZHANG Kangkang, SONG Jia, WEI Yilin, WANG Chunying, DONG Heng, CHEN Manwei, QING Hua. Specification for the Integration of Healthcare and Prevention Services in Hypertension at the Primary Level [J]. Chinese General Practice, 2025, 28(25): 3089-3095.
[7]	LIU Yinyin, SUI Hongping, LI Tingting, JIANG Tongtong, SHI Tieying, XIA Yunlong. Advances in Risk Prediction Models for Cardiotoxicity Associated with Breast Cancer Treatment [J]. Chinese General Practice, 2025, 28(24): 3072-3078.
[8]	LI Miaoxiu, ZHU Bowen, KONG Lingjun, FANG Min. Progress in Research on Clinical Assessment Tools for Conservative Treatment of Adolescent Idiopathic Scoliosis [J]. Chinese General Practice, 2025, 28(24): 3079-3088.
[9]	XIAO Yao, WAN Jun. Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants [J]. Chinese General Practice, 2025, 28(24): 3066-3071.
[10]	RUAN Wanbai, LI Junfeng, YIN Yanmei, PENG Lei, ZHU Kexiang. Research Progress of Targeted Therapy and Immunotherapy for Pancreatic Cancer [J]. Chinese General Practice, 2025, 28(23): 2950-2960.
[11]	ZHOU Lianpeng, LI Weifeng, DONG Xingang, WANG Xiaoyuan. Research Progress on the Role of Copper Homeostasis Regulation Mechanism in Cognition Disorder [J]. Chinese General Practice, 2025, 28(23): 2941-2949.
[12]	YANG Ji, ZHANG Yao, ZHAO Yingqiang, ZHANG Qiuyue. Evaluation of the Effectiveness of TCM Three-level Prevention and Control Model in the Management of Patients with Coronary Heart Disease and Stroke: a Single-center, Prospective Cohort Study [J]. Chinese General Practice, 2025, 28(22): 2750-2761.
[13]	DONG Haocheng, HAO Xiao, AN Dong, LI Haohan, LI Shuren. Research Progress of Heart Failure with Supra-normal Ejection Fraction [J]. Chinese General Practice, 2025, 28(21): 2692-2696.
[14]	DU Qiongliang, LIN Bailang, GUO Honghua. Research Progress and Implications of Group Well-child Care [J]. Chinese General Practice, 2025, 28(21): 2672-2678.
[15]	Chinese Geriatrics Society, General Practice Branch of Zhejiang Medical Association, the Expert Collaboration Group on Medically Unspecified Disease in General Practice. Expert Consensus on the Diagnosis, Treatment, and Management of Emaciation (2025) [J]. Chinese General Practice, 2025, 28(21): 2577-2594.